STRO Stock Forecast & Price Target

Sutro Biopharma is a clinical-stage drug discovery, development, and manufacturing company that specializes in next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. With a growing pipeline of clinical candidates, a solid cash position of $212MM (pro forma), and the potential for STRO-004 to report best-in-class efficacy and safety by mid-2026, the company's shares are undervalued. Key factors that contribute to this positive outlook include the platform's ability to produce aglycosylated, Fc-configurable antibodies rapidly and reproducibly, the potential for dual-payload designs that combine cytotoxins and immune stimulators at controlled ratios, and the company's partnership with Astellas for dual-payload immunostimulatory ADCs.

Sutro Biopharma is facing a critical milestone in mid-2026 with the expected release of initial clinical data from STRO-004, which will be the first evidence of proof-of-concept for their ADC platform. Despite promising preclinical data, investors will closely monitor the company's ability to translate this improved tolerability profile into clinical success, especially in light of past challenges with previous tissue factor-targeting agents. The broader pipeline's progress will also be crucial in assessing the company's capital structure and allocation decisions.